Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Certara2024年12月11日
Optimizing Clinical Development: Saving Time and Costs Case Study 臨床開発の最適化:時間とコストを削減 Strategic Mechanisticモデリングソリューションは、免疫療法のバイオテクノロジー企業が新規治療法の臨床開発を加速させるのに役立ちます。Certara2024年8月16日
Systems Modeling Delivers Efficiencies and Savings in Clinical Development Case Study システムモデリングが臨床開発の効率化とコスト削減を実現 Discover how an IO-focused company developing immunotherapies applied QSP modeling solutions for cost-effective clinical development.…Certara2024年7月12日
Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm Publication Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit…Certara2020年7月26日